Shopping Cart
Remove All
Your shopping cart is currently empty
Synonyms: MRT-6160


| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $66 | In Stock | In Stock | |
| 5 mg | $158 | In Stock | In Stock | |
| 10 mg | $228 | In Stock | In Stock | |
| 25 mg | $396 | In Stock | In Stock | |
| 50 mg | $538 | In Stock | In Stock | |
| 100 mg | $795 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $176 | In Stock | In Stock |
| Description | VAV1 degrader-3 is an orally active and efficient VAV1 molecular glue degrader that reduces immune cell activation, proliferation, and cytokine production, useful for studying inflammation and autoimmune diseases. |
| In vitro | VAV1 degrader-3 (0-1μM, 24h) induces VAV1 degradation, thereby reducing CD69 expression mediated by the B cell receptor and the secretion of IL-6 and IgG in primary human B cells.
VAV1 degrader-3 inhibits the growth of B lymphoma cells in a concentration-dependent manner. [1] |
| In vivo | VAV1 degrader-3 (1-10 mg/kg, oral) inhibits the progression of experimental autoimmune encephalomyelitis (EAE) in the EAE mouse model in a dose-dependent manner.
In the T cell transfer-induced colitis model, VAV1 degrader-3 (1 mg/kg, oral) inhibited colitis. In the collagen-induced arthritis model, VAV1 degrader-3 (1 mg/kg, 21 days, oral) reduced the production of anti-collagen II IgG1 antibodies and prevented the progression of arthritis. [1] |
| Synonyms | MRT-6160 |
| Molecular Weight | 392.84 |
| Formula | C22H17ClN2O3 |
| Cas No. | 3050683-38-7 |
| Smiles | O=C1C=CC=CN1C2=CC=C(C=C2)C=3C=CC=C(C3Cl)C4C(=O)NC(=O)CC4 |
| Relative Density. | no data available |
| Storage | Keep away from moisture Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 51.7 mg/mL (131.61 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+90% Saline: 5.17 mg/mL (13.16 mM), Suspension. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 µL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 µL Tween 80 and mix well until fully clarified.
3) Add 450 µL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.